Literature DB >> 14977093

Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal.

Christopher Evans1, Manouche Tavakoli, Bruce Crawford.   

Abstract

Researchers have grappled with various ways of placing the results of an economic evaluation in the appropriate context. One of the most common methods is to relate the results of a study to an appropriate benchmark (commonly, dollars 50,000 per QALY in the US or pounds sterling 30,000 per QALY in the UK). This paper examines the foundation for these cut-off points and critiques their use by researchers. Although it is difficult to establish an appropriate benchmark this paper notes that reference points may be too low based on published data. Further, the inconsistent application of benchmarks, and differences in the calculation of a value of a statistical life, will lead to an inefficient allocation of health care resources.

Mesh:

Year:  2004        PMID: 14977093     DOI: 10.1023/b:hcms.0000005397.93173.bb

Source DB:  PubMed          Journal:  Health Care Manag Sci        ISSN: 1386-9620


  32 in total

1.  Opportunity costs and uncertainty in the economic evaluation of health care interventions.

Authors:  P Sendi; A Gafni; S Birch
Journal:  Health Econ       Date:  2002-01       Impact factor: 3.046

2.  Cost-effectiveness analysis of interferon as adjuvant therapy in high-risk melanoma patients in Spain.

Authors:  J L González-Larriba; S Serrano; M Alvarez-Mon; F Camacho; M A Casado; J L Díaz-Pérez; E Díaz-Rubio; L Fosbrook; V Guillem; J J López-López; J A Moreno-Nogueira; J Toribio
Journal:  Eur J Cancer       Date:  2000-12       Impact factor: 9.162

3.  Limitations of the methods used for calculating quality-adjusted life-year values.

Authors:  Gérard Duru; Jean Paul Auray; Ariel Béresniak; Michel Lamure; Abby Paine; Nicolas Nicoloyannis
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 4.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?

Authors:  S Birch; A Gafni
Journal:  J Health Econ       Date:  1992-10       Impact factor: 3.883

5.  QALYs and the equity-efficiency trade-off.

Authors:  A Wagstaff
Journal:  J Health Econ       Date:  1991-05       Impact factor: 3.883

6.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

7.  Cost-effectiveness of captopril therapy after myocardial infarction.

Authors:  J Tsevat; D Duke; L Goldman; M A Pfeffer; G A Lamas; J R Soukup; K M Kuntz; T H Lee
Journal:  J Am Coll Cardiol       Date:  1995-10       Impact factor: 24.094

8.  Cost-effectiveness league tables: more harm than good?

Authors:  M Drummond; G Torrance; J Mason
Journal:  Soc Sci Med       Date:  1993-07       Impact factor: 4.634

9.  Incorporating societal concerns for fairness in numerical valuations of health programmes.

Authors:  E Nord; J L Pinto; J Richardson; P Menzel; P Ubel
Journal:  Health Econ       Date:  1999-02       Impact factor: 3.046

10.  Distributing scarce livers: the moral reasoning of the general public.

Authors:  P A Ubel; G Loewenstein
Journal:  Soc Sci Med       Date:  1996-04       Impact factor: 4.634

View more
  25 in total

Review 1.  Taking account of future technology in cost effectiveness analysis.

Authors:  Joshua A Salomon; Milton C Weinstein; Sue J Goldie
Journal:  BMJ       Date:  2004-09-25

Review 2.  A review of health care models for coronary heart disease interventions.

Authors:  K Cooper; S C Brailsford; R Davies; J Raftery
Journal:  Health Care Manag Sci       Date:  2006-11

Review 3.  Bias in published cost effectiveness studies: systematic review.

Authors:  Chaim M Bell; David R Urbach; Joel G Ray; Ahmed Bayoumi; Allison B Rosen; Dan Greenberg; Peter J Neumann
Journal:  BMJ       Date:  2006-02-22

4.  Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis.

Authors:  Rachael L Fleurence; D Eldon Spackman; Christopher Hollenbeak
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 5.  Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.

Authors:  Patricia R Blank; Konstantin J Dedes; Thomas D Szucs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  The distribution over time of costs and social net benefits for pertussis immunization programs.

Authors:  Dorota Zdanowska Girard
Journal:  Int J Health Care Finance Econ       Date:  2009-03-18

8.  The value of single-pathogen antibacterial agents.

Authors:  Brad Spellberg; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2013-11-15       Impact factor: 84.694

9.  Decision Analysis and Cost-effectiveness Analysis.

Authors:  Hilary F Ryder; Christine McDonough; Anna N A Tosteson; Jon D Lurie
Journal:  Semin Spine Surg       Date:  2009-12

Review 10.  A look at statin cost-effectiveness in view of the 2013 ACC/AHA cholesterol management guidelines.

Authors:  Roderick C Deaño; Ankur Pandya; Erica C Jones; William B Borden
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.